Hanmi Pharm. Co., Ltd. (128940.KS)
KRW 269500.0
(-1.46%)
KRW 269500.0
(-1.46%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 82.02 Billion KRW | -63.67% |
| 2022 | 225.81 Billion KRW | -25.0% |
| 2021 | 301.09 Billion KRW | -24.8% |
| 2020 | 400.41 Billion KRW | -27.58% |
| 2019 | 552.94 Billion KRW | 33.0% |
| 2018 | 415.75 Billion KRW | 110.34% |
| 2017 | 197.65 Billion KRW | 22.83% |
| 2016 | 160.91 Billion KRW | -39.1% |
| 2015 | 264.23 Billion KRW | 17.25% |
| 2014 | 225.35 Billion KRW | 47.19% |
| 2013 | 153.1 Billion KRW | 29.71% |
| 2012 | 118.03 Billion KRW | -33.39% |
| 2011 | 177.2 Billion KRW | 20.11% |
| 2010 | 147.52 Billion KRW | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 66.84 Billion KRW | -10.2% |
| 2024 Q1 | 74.43 Billion KRW | -9.26% |
| 2023 Q4 | 82.02 Billion KRW | -26.81% |
| 2023 Q1 | 218.08 Billion KRW | -3.42% |
| 2023 FY | 82.02 Billion KRW | -63.67% |
| 2023 Q3 | 112.08 Billion KRW | -21.16% |
| 2023 Q2 | 142.16 Billion KRW | -34.81% |
| 2022 Q4 | 225.81 Billion KRW | -0.89% |
| 2022 FY | 225.81 Billion KRW | -25.0% |
| 2022 Q1 | 283.35 Billion KRW | -5.89% |
| 2022 Q2 | 235.66 Billion KRW | -16.83% |
| 2022 Q3 | 227.85 Billion KRW | -3.31% |
| 2021 Q2 | 293.72 Billion KRW | -27.92% |
| 2021 Q1 | 407.5 Billion KRW | 1.77% |
| 2021 Q3 | 300.27 Billion KRW | 2.23% |
| 2021 FY | 301.09 Billion KRW | -24.8% |
| 2021 Q4 | 301.09 Billion KRW | 0.27% |
| 2020 Q3 | 444.8 Billion KRW | -7.79% |
| 2020 Q2 | 482.4 Billion KRW | -11.39% |
| 2020 FY | 400.41 Billion KRW | -27.58% |
| 2020 Q1 | 544.39 Billion KRW | -1.55% |
| 2020 Q4 | 400.41 Billion KRW | -9.98% |
| 2019 Q2 | 532.06 Billion KRW | 31.17% |
| 2019 FY | 552.94 Billion KRW | 33.0% |
| 2019 Q4 | 552.94 Billion KRW | 4.39% |
| 2019 Q3 | 529.69 Billion KRW | -0.44% |
| 2019 Q1 | 405.61 Billion KRW | -2.44% |
| 2018 Q4 | 415.75 Billion KRW | 17.31% |
| 2018 Q3 | 354.41 Billion KRW | -0.26% |
| 2018 Q2 | 355.35 Billion KRW | 63.99% |
| 2018 FY | 415.75 Billion KRW | 110.34% |
| 2018 Q1 | 216.68 Billion KRW | 9.63% |
| 2017 Q4 | 197.65 Billion KRW | -2.7% |
| 2017 FY | 197.65 Billion KRW | 22.83% |
| 2017 Q2 | 219.03 Billion KRW | 15.3% |
| 2017 Q3 | 203.13 Billion KRW | -7.26% |
| 2017 Q1 | 189.97 Billion KRW | 18.06% |
| 2016 Q2 | 200.21 Billion KRW | 0.0% |
| 2016 Q4 | 160.91 Billion KRW | 0.43% |
| 2016 Q3 | 160.22 Billion KRW | -19.97% |
| 2016 FY | 160.91 Billion KRW | -39.1% |
| 2016 Q1 | 200.21 Billion KRW | -24.23% |
| 2015 Q3 | 268.71 Billion KRW | 0.02% |
| 2015 Q1 | 233.66 Billion KRW | 3.69% |
| 2015 Q2 | 268.65 Billion KRW | 14.97% |
| 2015 FY | 264.23 Billion KRW | 17.25% |
| 2015 Q4 | 264.23 Billion KRW | -1.67% |
| 2014 Q1 | 177.92 Billion KRW | 16.21% |
| 2014 FY | 225.35 Billion KRW | 47.19% |
| 2014 Q2 | 217.54 Billion KRW | 22.27% |
| 2014 Q4 | 225.35 Billion KRW | 3.76% |
| 2014 Q3 | 217.18 Billion KRW | -0.16% |
| 2013 Q4 | 153.1 Billion KRW | -4.15% |
| 2013 Q2 | 95.52 Billion KRW | 9.83% |
| 2013 FY | 153.1 Billion KRW | 29.71% |
| 2013 Q1 | 86.97 Billion KRW | -26.32% |
| 2013 Q3 | 159.72 Billion KRW | 67.21% |
| 2012 FY | 118.03 Billion KRW | -33.39% |
| 2012 Q2 | 196.66 Billion KRW | -5.34% |
| 2012 Q3 | 125.73 Billion KRW | -36.07% |
| 2012 Q4 | 118.03 Billion KRW | -6.12% |
| 2012 Q1 | 207.74 Billion KRW | 0.0% |
| 2011 Q2 | 139.79 Billion KRW | 0.02% |
| 2011 Q3 | 159.68 Billion KRW | 14.23% |
| 2011 FY | 177.2 Billion KRW | 20.11% |
| 2011 Q1 | 139.77 Billion KRW | 0.0% |
| 2010 Q3 | 134.72 Billion KRW | 0.0% |
| 2010 FY | 147.52 Billion KRW | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 13.64 Billion KRW | -501.379% |
| Dong-A Socio Holdings Co., Ltd. | 202.06 Billion KRW | 59.404% |
| Ildong Holdings Co., Ltd. | 29.87 Billion KRW | -174.557% |
| HANDOK Inc. | 123.78 Billion KRW | 33.731% |
| Kukje Pharma Co., Ltd. | 475.74 Million KRW | -17142.174% |
| Yuhan Corporation | 60.23 Billion KRW | -36.183% |
| Dong-A ST Co., Ltd. | 161.99 Billion KRW | 49.363% |
| SAMSUNG PHARM. Co., LTD. | 101.81 Million KRW | -80463.917% |
| Hanall Biopharma Co.,Ltd | 590.3 Million KRW | -13795.837% |
| Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | -1255.841% |
| Dong Sung Bio Pharm.Co.,Ltd. | 18.52 Billion KRW | -342.86% |
| MYUNGMOON Pharm co.,Ltd | 12.58 Billion KRW | -551.836% |
| Hana Pharm Co., Ltd. | 1.59 Billion KRW | -5030.476% |
| Yuyu Pharma, Inc. | 13.64 Billion KRW | -501.379% |
| Ilsung Pharmaceuticals Co., Ltd. | 119.67 Million KRW | -68440.689% |
| REYON Pharmaceutical Co., Ltd. | 121 Billion KRW | 32.208% |
| Aprogen pharmaceuticals,Inc. | 32 Billion KRW | -156.339% |
| JW Holdings Corporation | 20.65 Billion KRW | -297.091% |
| Ildong Pharmaceutical Co., Ltd. | 14.82 Billion KRW | -453.305% |
| Chong Kun Dang Pharmaceutical Corp. | 30 Billion KRW | -173.428% |
| JW Pharmaceutical Corporation | 30 Billion KRW | -173.428% |
| Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | -37362.562% |
| Hyundai Pharmaceutical Co., Ltd. | 580.64 Million KRW | -14027.09% |
| Samil Pharmaceutical Co.,Ltd | 49.56 Billion KRW | -65.485% |
| Jeil Pharmaceutical Co.,Ltd | 4.45 Billion KRW | -1742.505% |
| Yuyu Pharma, Inc. | 13.64 Billion KRW | -501.379% |
| Kwang Dong Pharmaceutical Co., Ltd. | 19.02 Billion KRW | -331.101% |
| Daewoong pharmaceutical Co.,Ltd | 93.41 Billion KRW | 12.19% |
| JW Pharmaceutical Corporation | 30 Billion KRW | -173.428% |
| Yuhan Corporation | 60.23 Billion KRW | -36.183% |
| Jeil Pharma Holdings Inc | 10.5 Billion KRW | -681.223% |
| Yungjin Pharm. Co., Ltd. | 40.37 Billion KRW | -103.152% |
| Suheung Co., Ltd. | 74 Billion KRW | -10.839% |
| JW Pharmaceutical Corporation | 30 Billion KRW | -173.428% |
| Samjin Pharmaceuticals Co., Ltd. | 4.16 Billion KRW | -1868.694% |
| Korea United Pharm Inc. | 10.96 Billion KRW | -648.264% |
| CKD Bio Corp. | 69.43 Billion KRW | -18.143% |
| Daewon Pharmaceutical Co., Ltd. | 34.57 Billion KRW | -137.249% |
| Dongwha Pharm.Co.,Ltd | 16.12 Billion KRW | -408.619% |
| Whan In Pharm Co.,Ltd. | 307.05 Million KRW | -26614.456% |
| Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | -37362.562% |
| Chong Kun Dang Holdings Corp. | 72.11 Billion KRW | -13.751% |
| Boryung Corporation | 151.7 Billion KRW | 45.93% |
| Bukwang Pharmaceutical Co., Ltd. | 78.52 Billion KRW | -4.461% |
| Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | -1255.841% |
| JW Lifescience Corporation | 168 Million KRW | -48726.429% |